174313-65-6

Basic information

• Product Name: 6-BroMo-2-(Methylthio)-4(3H)-quinazolinone
• Synonyms: 6-BroMo-2-(Methylthio)-4(3H)-quinazolinone;6-bromo-2-(methylsulfanyl)-3,4-dihydroquinazolin-4-one;6-Bromo-2-(methylthio)quinazolin-4(3H)-one
• CAS NO: 174313-65-6
• Molecular Formula: C₉H₇BrN₂OS
• Molecular Weight: 271.13368
• Mol File: 174313-65-6.mol
• Article Data: 6

Chemical Properties

• Melting Point: 230 °C
• Boiling Point: 418.5±47.0 °C(Predicted)
• Appearance: /
• Density: 1.76±0.1 g/cm3(Predicted)
• PKA: -0.90±0.20(Predicted)
• CAS DataBase Reference: 6-BroMo-2-(Methylthio)-4(3H)-quinazolinone(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BroMo-2-(Methylthio)-4(3H)-quinazolinone(174313-65-6)
• EPA Substance Registry System: 6-BroMo-2-(Methylthio)-4(3H)-quinazolinone(174313-65-6)

Safety Data

• Hazardous Substances Data: 174313-65-6(Hazardous Substances Data)

Usage

General Description

6-Bromo-2-(methylthio)-4(3H)-quinazolinone, also known as NSC77653, is a chemical compound with potential applications in the field of pharmaceuticals and drug development. It is a quinazolinone derivative with a bromine atom and a methylthio group attached to the quinazoline ring structure. 6-BroMo-2-(Methylthio)-4(3H)-quinazolinone has shown promise as an anti-tumor agent and has exhibited cytotoxic effects on various cancer cell lines in research studies. Additionally, 6-Bromo-2-(methylthio)-4(3H)-quinazolinone has demonstrated potential for use in the treatment of inflammatory and autoimmune diseases. Its precise mechanisms of action and potential side effects are still under investigation, but it represents a promising candidate for further pharmacological studies and drug development efforts.

Upstream product

• 49681-94-9 6-Methyl-4-oxo-2-thioxo-1,2,3,4-tetrahydrochinazolin 
• 74-88-4 methyl iodide 
• 49681-96-1 6-bromo-2-mercaptoquinazolin-4-ol 
• 49681-96-1 6-bromo-2,3-dihydro-2-thioxo-quinazolin-4(3H)-one 
• 118-48-9 isatoic anhydride 
• 4692-98-2 5-bromoisatoic anhydride 

Downstream Products

• 1003043-76-2 6-bromo-4-chloro-2-(methylsulfanyl)quinazoline 
• 1189798-00-2 benzyl (2E)-3-[2-(4-methylphenyl)-3,5-dioxo-2,6-dihydro-[1,2,4]triazolo[4,3-c]quinazolin-9-yl]acrylate 
• 1189797-76-9 9-benzyl-2-(4-methylphenyl)-2,6-dihydro[1,2,4]triazolo-[4,3-c]quinazoline-3,5-dione 
• 1189797-84-9 9-bromo-2-(4-methylphenyl)-5-(methylsulfanyl)[1,2,4]-triazolo[4,3-c]quinazolin-3(2H)-one 
• 1189797-63-4 9-bromo-2-(4-methylphenyl)-2,6-dihydro[1,2,4]triazolo-[4,3-c]quinazoline-3,5-dione 

Relevant articles and documents

Triazoloquinazolinediones as novel high affinity ligands for the benzodiazepine site of GABAA receptors

Based on a pharmacophore model of the benzodiazepine-binding site of GABAA receptors, a series of 2-aryl-2,6-dihydro[1,2,4]triazolo[4,3-c] quinazoline-3,5-diones (structure type I) were designed, synthesized, and identified as high-affinity lig

4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS

This invention provides the treatment of viral infections with a 4,6- disubstituted or 2,4,6-trisubstituted quinazoline derivative represented by the structural formula [(I)] wherein: R2 is selected from the group consisting of hydrogen, NR'R"

4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES HAVING CCR3 ANTAGONISM

The invention provides low molecular compounds having activity which inhibits binding of CCR3 ligands to CCR3 on target cells, i.e. CCR3 antagonists. The invention also provides 4,4-(disubstituted)piperidine derivatives represented by formula (I) below, pharmaceutically acceptable acid adducts thereof, or pharmaceutically acceptable C1-C6 alkyl adducts thereof, as well as pharmaceutical compositions comprising them as effective ingredients, which are useful for treatment or prevention of diseases associated with CCR3, such as asthma and allergic rhinitis.